1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models

Cancer

Volumn 116, Issue 13, 2010, Pages 3294-3303

  Ma, Yingyu ^a   Yu, Wei Dong ^a   Trump, Donald L ^a   Johnson, Candace S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

1, 25d3; Bladder cancer; Cisplatin; Gemcitabine; P73

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CALCITRIOL; CASPASE; CISPLATIN; GEMCITABINE; LIPOCORTIN 5; PROTEIN P73; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; CALCITRIOL RECEPTOR; DEOXYCYTIDINE; DIHYDROXY VITAMIN D3; DIHYDROXY-VITAMIN D3; DNA BINDING PROTEIN; DRUG DERIVATIVE; NUCLEAR PROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CANCER MODEL; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; BLADDER TUMOR; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CALCITRIOL; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DEOXYCYTIDINE; DNA-BINDING PROTEINS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; MICE; MICE, NUDE; NUCLEAR PROTEINS; RECEPTORS, CALCITRIOL; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS; VITAMIN D; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954277193     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25059     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Sternberg CN, Donat SM, Bellmunt J, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology. 2007;69(suppl 1):62-79.
3. Barocas DA, Clark PE. Bladder cancer. Curr Opin Oncol. 2008;20:307-314.
4. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7:573-584.
5. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-beta-D-arabinofuranosyl-cytosine. Cancer Res. 1988;48:4024-4031.
6. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol. 2006;17(suppl 5):v7-v12.
7. Gong JG, Costanzo A, Yang HQ, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature. 1999;399:806-809. (Pubitemid 29293179)
8. Thottassery JV, Westbrook L, Someya H, Parker WB. c-Abl-independent p73 stabilization during gemcitabine- or 4′-thio-beta-D- arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells. Mol Cancer Ther. 2006;5:400-410.
9. Melino G, De Laurenzi V, Vousden KH. p73: Friend or foe in tumorigenesis. Nat Rev Cancer. 2002;2:605-615.
10. Tomasini R, Tsuchihara K, Wilhelm M, et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev. 2008;22:2677-2691.
11. Puig P, Capodieci P, Drobnjak M, et al. p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. Clin Cancer Res. 2003;9:5642-5651. (Pubitemid 37499486)
12. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007;7:684-700.
13. Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health. 2006;96:252-261.
14. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst. 2006;98:451-459.
15. Giovannucci E, Liu Y, Stampfer MJ, Willett WC. A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:203-210. (Pubitemid 43342165)
16. Giovannucci E. Vitamin D and cancer incidence in the Harvard cohorts. Ann Epidemiol. 2009;19:84-88.
17. Ng K, Meyerhardt JA, Wu K, et al. Circulating 25-hydroxy-vitamin d levels and survival in patients with colorectal cancer. J Clin Oncol. 2008;26:2984-2991.
18. Kilkkinen A, Knekt P, Heliovaara M, et al. Vitamin D status and the risk of lung cancer: a cohort study in Finland. Cancer Epidemiol Biomarkers Prev. 2008;17:3274-3278.
19. Ma Y, Yu WD, Kong RX, Trump DL, Johnson CS. Role of nongenomic activation of phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase 1/2 pathways in 1,25d3-mediated apoptosis in squamous cell carcinoma cells. Cancer Res. 2006;66:8131-8138.
20. Yu WD, McElwain MC, Modzelewski RA, et al. Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst. 1998;90:134-141.
21. Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res. 2001;7:1043-1051.
22. Ahmed S, Johnson CS, Rueger RM, Trump DL. Calcitriol (1,25- dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model. J Urol. 2002;168:756-761.
23. Ma Y, Yu WD, Hershberger PA, et al. 1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model. Mol Cancer Ther. 2008;7:3047-3055.
24. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068-3077.
25. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4:307-320. (Pubitemid 41130944)
26. Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat. 2002;5:19-33.
27. Hershberger PA, McGuire TF, Yu WD, et al. Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol Cancer Ther. 2002;1:821-829.
28. Ravid A, Rocker D, Machlenkin A, et al. 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res. 1999;59:862-867.
29. Wang Q, Yang W, Uytingco MS, Christakos S, Wieder R. 1,25- Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. Cancer Res. 2000;60:2040-2048.
30. Hermann GG, Andersen CB. Transitional cell carcinoma express vitamin D receptors. Scand J Urol Nephrol. 1997;31:161-166. (Pubitemid 27213905)
31. Sahin MO, Canda AE, Yorukoglu K, Mungan MU, Sade M, Kirkali Z. 1,25 Dihydroxyvitamin D receptor expression in superficial transitional cell carcinoma of the bladder: a possible prognostic factor? Eur Urol. 2005;47:52-57.
32. Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res. 1997;57:3759-3764.
33. Konety BR, Lavelle JP, Pirtskalaishvili G, et al. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol. 2001;165:253-258.
34. Habuchi T, Ogawa O, Kakehi Y, et al. Allelic loss of chromosome 17p in urothelial cancer: strong association with invasive phenotype. J Urol. 1992;148:1595-1599.
35. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG Jr. Chemosensitivity linked to p73 function. Cancer Cell. 2003;3:403-410.
36. Bergamaschi D, Gasco M, Hiller L, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 2003;3:387-402.
37. Bell HS, Dufes C, O'Prey J, et al. A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J Clin Invest. 2007;117:1008-1018.
38. Cunningham D, Gilchrist NL, Cowan RA, Forrest GJ, McArdle CS, Soukop M. Alfacalcidol as a modulator of growth of low grade non-Hodgkin's lymphomas. BMJ (Clin Res Ed). 1985;291:1153-1155. (Pubitemid 15246953)
39. Koeffler HP, Hirji K, Itri L. 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep. 1985;69:1399-1407.
40. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL. A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res. 1999;5:1339-1345.
41. Beer TM, Munar M, Henner WD. A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer. 2001;91:2431-2439. (Pubitemid 32552832)
42. Muindi JR, Peng Y, Potter DM, et al. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther. 2002;72:648-659. (Pubitemid 36021004)
43. Beer TM, Javle MM, Ryan CW, et al. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol. 2007;59:581-587. (Pubitemid 46295122)
44. Trump DL, Hershberger PA, Bernardi RJ, et al. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol. 2004;89-90:519-526.